Dwight Blake, MD
Internal Medicine · Union City, GANPI 1811938814
Payments from drug & device makers
What this record shows
10 manufacturers reported payments, led by Eli Lilly at 39.6% of the total. Reporting peaked in 2024 at $1,819 and has fallen 79.7% since, to $369 in 2025. Among internal medicine clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 44 payments — averaging $115.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$2K
- Pfizer$2K
- AstraZeneca$506
- Novo Nordisk$330
- Dexcom, Inc.$127
- Metuchen Pharmaceuticals$125
- plus $280 from 4 others
Across 274 payments — averaging $49,270 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$10.5M
- Pfizer$1.2M
- Amgen$877K
- Genentech, Inc.$399K
- Hoffmann-la Roche Limited$217K
- AbbVie$94K
- plus $265K from 5 others
What the payments were for
- Travel & lodging$2,78055%
- Food & beverage$2,30245%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 26 | $2,014 |
| Pfizer | 4 | $1,700 |
| AstraZeneca | 5 | $506 |
| Novo Nordisk | 3 | $330 |
| Dexcom, Inc. | 1 | $127 |
| Metuchen Pharmaceuticals | 1 | $125 |
| Lilly USA, LLC | 1 | $122 |
| Boehringer Ingelheim | 1 | $117 |
| Alkermes, Inc. | 1 | $24 |
| Currax Pharmaceuticals LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,082 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 58 | $77,592 |
| EliquisApixaban | 59 | $65,383 |
| MounjaroTirzepatide | 34 | $56,839 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $47,179 |
| JardianceEmpagliflozin | 22 | $28,012 |
| FarxigaDapagliflozin Propanediol | 39 | $27,027 |
| TrulicityDulaglutide | 14 | $22,703 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $16,558 |
| Famotidine | 58 | $3,527 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 16 | $3,466 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 86 | $2,890 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $2,849 |
| PremarinEstrogens, Conjugated | 21 | $2,774 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 39 | $2,745 |
| LantusInsulin Glargine,hum.Rec.Anlog | 16 | $2,695 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $122 | $79,54248 claims |
| Novo NordiskOzempic | $330 | $77,59258 claims |
| PfizerEliquis, Premarin | $1,700 | $68,15780 claims |
| Boehringer IngelheimJardiance | $117 | $28,01222 claims |
| AstraZenecaFarxiga | $506 | $27,02739 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Union City
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.